Non-regulatory pre-clinical review
last phase of drug development
updated 30 Sep 2014
Two interesting candidates from the fenarimol series of compounds were identified through lead optimization efforts. In 2013, the project was in its non-regulatory preclinical phase, with further profiling of candidates, before nominating one candidate for progression into regulatory pre-clinical development. The objective was to perform Good Laboratory Practice (GLP) safety studies, as well as Chemistry, Manufacturing, and Control (CMC) studies on the selected candidate compound, in order to file a formal investigational new drug (IND) application and move the candidate to first-in-man studies. However, given the lack of sustained efficacy of azoles (E1224 and posaconazole) in clinical trials for Chagas diseases, this project has been stopped.
Get our latest news, personal stories, research articles, and job opportunities.